Addressing Knowledge Gaps in Acute Myeloid Leukemia to Improve Referral for Hematopoietic Cell Transplantation Consultation
Center for International Blood and Marrow Transplantation, Minneapolis, Minnesota.
Search for other papers by Christa Meyer in
Current site
Google Scholar
PubMed
Center for International Blood and Marrow Transplantation, Minneapolis, Minnesota.
Search for other papers by Lih-Wen Mau in
Current site
Google Scholar
PubMed
Center for International Blood and Marrow Transplantation, Minneapolis, Minnesota.
Search for other papers by Elizabeth A. Murphy in
Current site
Google Scholar
PubMed
Center for International Blood and Marrow Transplantation, Minneapolis, Minnesota.
Search for other papers by Ellen M. Denzen in
Current site
Google Scholar
PubMed
Search for other papers by Ellyce Hayes in
Current site
Google Scholar
PubMed
Search for other papers by Darlene Haven in
Current site
Google Scholar
PubMed
Search for other papers by Heather Moore in
Current site
Google Scholar
PubMed
Search for other papers by Jackie Foster in
Current site
Google Scholar
PubMed
Center for International Blood and Marrow Transplantation, Minneapolis, Minnesota.
Search for other papers by Jaime M. Preussler in
Current site
Google Scholar
PubMed
Center for International Blood and Marrow Transplantation, Minneapolis, Minnesota.
Search for other papers by Linda J. Burns in
Current site
Google Scholar
PubMed
Background: Outcomes after hematopoietic cell transplantation (HCT) for acute myeloid leukemia (AML) are better when HCT is performed during first complete remission (CR1). This study aimed to identify and address knowledge gaps that affect the timely referral of patients for HCT consultation. Methods: A mixed-methods educational needs assessment included a national survey and focus groups consisting of hematologists/oncologists. An educational intervention of 3 webinars addressed identified knowledge gaps. Results: A total of 150 hematologists/oncologists were recruited for the survey, of whom 20 participated in focus groups. Physicians in practice 0 to 10 years were 4.2 times more likely to refer for HCT consultation in CR1 than those with >10 years in practice (P=.0027). Physicians seeing ≤10 patients with AML in the past year were 3.7 times more likely to refer for HCT consultation in CR1 than those seeing >10 patients (P=.0028). Knowledge gaps included (1) improper classification of molecular/cytogenetic results for risk stratification, (2) lack of understanding that disease stage impacts outcomes, and (3) use of chronologic age alone for referral decision-making. Combined attendance for the webinars was 1,098 clinicians; >74% of participants indicated that they would apply the knowledge they gained in clinical practice. Trends were observed toward improvement in identifying favorable-risk AML, from 48% to 60% (n=85; P=.12); improvement in identifying 2 poor-risk cytogenetic/molecular abnormalities, with the percentage of respondents indicating chromosome 7 deletion increasing from 51% to 70% (n=53; P=.05) and that of respondents indicating TP53 mutation increasing from 42% to 62% (n=62; P=.03); and improvement in identifying which patients with AML aged >60 years were most likely to benefit from HCT based on cytogenetic/molecular features, with the percentage of correct responses increasing from 66% to 81% (n=62; P=.07). Conclusions: The webinars met the educational needs of learners and improved knowledge gaps. This study provided novel insights into the learning needs of clinicians who care for patients with AML and a roadmap for future educational interventions.
Submitted November 2, 2018; accepted for publication June 6, 2019.
Author contributions: Study concept and design: All authors. Data analysis: Meyer, Mau, Burns. Manuscript preparation: All authors. Manuscript approval: All authors.
Disclosures: Ms. Haven has disclosed that she owned stock in Pfizer during the study. Ms. Foster has disclosed that her spouse owned stock in Pfizer during the study. The remaining authors have disclosed that they have not received any financial considerations from any person or organization to support the preparation, analysis, results, or discussion of this article.
© 2019-2024 National Comprehensive Cancer Network